共 93 条
[1]
Finn RS(2018)Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) Breast Cancer Res Treat 18 17-173
[2]
Aleshin A(2016)Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers Breast Cancer Res 11 167-35
[3]
Slamon DJ(2016)Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer Breast Care (Basel). 10 97-219
[4]
Barroso-Sousa R(2017)Recent advances of highly selective CDK4/6 inhibitors in breast cancer J Hematol Oncol 16 25-439
[5]
Shapiro GI(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 373 209-1936
[6]
Tolaney SM(2015)Cristofanilli M; PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 17 425-1748
[7]
Xu H(2016)Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 375 1925-5224
[8]
Yu S(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1738-2884
[9]
Liu Q(2016)Ribociclib as first-line therapy for hr-positive, advanced breast cancer N Engl J Med 23 5218-583
[10]
Yuan X(2017)MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer Clin Cancer Res 35 2875-5130